US Cancer Drug Shortages Raise Concerns for Global Supply Chains

A new survey by the National Comprehensive Cancer Network (NCCN) reveals widespread shortages of essential cancer medications across the United States. All 31 cancer centers that responded to the survey reported a lack of at least one oncology drug, with over a fifth experiencing shortages of five or more. The most critical shortage identified was for iphosphamide, a generic chemotherapy drug used to treat various cancers, including bladder, ovarian, and testicular cancers. Ninety-four percent of the surveyed centers reported a lack of this vital medication.

Central platinum-based chemotherapy drugs also showed significant shortages, with 71% of centers reporting a lack of carboplatin and 16% lacking cisplatin. These drugs are fundamental components of treatment protocols for numerous types of tumors. Additionally, more than half of the centers reported a shortage of BCG, an immunotherapy used for specific types of bladder cancer.

The implications of these drug shortages extend beyond simply halting treatment. Medical teams may be forced to alter dosages, change treatment schedules, or switch to alternative medications when possible. When treatment plans are modified due to shortages, 90% of centers reported needing to re-initiate prior authorization processes with insurance companies, increasing administrative burdens and potentially delaying patient care.

The survey highlights that many of the shortages involve older, generic drugs that form the basis of many cancer treatments. Nearly all pharmacy directors surveyed by NCCN supported the creation of financial incentives to ensure the stable and high-quality production of generic cancer drugs. There is concern that medications that are medically essential but less economically viable for manufacturers will remain susceptible to supply chain disruptions.

While the survey focused on 31 leading US cancer centers and does not represent a complete census of all facilities nationwide, the fact that every responding center reported some level of shortage indicates a broad and persistent issue. The article notes that there is no direct evidence of a parallel shortage in Israel based on these findings. However, the US crisis underscores the vulnerability of global supply chains for essential, older medications, particularly generic ones.